Idera Pharmaceuticals To Present Positive Phase 1 Trial Results On TLR Antagonist IMO-8400 For The Treatment Of Autoimmune Diseases At FOCIS 2013

Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) today announced that it will present positive Phase 1 trial results on IMO-8400, a selective inhibitor of Toll-like receptors (TLRs) 7, 8 and 9 and a lead candidate for the treatment of autoimmune diseases, at the 13 th Annual Meeting of the Federation of Clinical Immunology Societies (FOCIS), June 27-30, 2013, in Boston, MA.

Details of the presentation are as follows:

Saturday, June 29, 2013

6:30-7:45pm ET

Commonwealth Hall, The Boston Seaport Hotel

Abstract Number:

Phase 1 clinical trial of IMO-8400, an antagonist of Toll-like receptors 7, 8 and 9

About Idera Pharmaceuticals, Inc.

Idera Pharmaceuticals applies its proprietary Toll-like receptor (TLR) drug discovery platform to create immunomodulatory drug candidates and has a clinical development program in autoimmune diseases. Additionally, Idera has a collaboration with Merck & Co. for the use of TLR-targeted candidates as vaccine adjuvants for cancer, infectious diseases and Alzheimer’s disease. For more information, visit

Copyright Business Wire 2010